JP2012526149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526149A5 JP2012526149A5 JP2012510041A JP2012510041A JP2012526149A5 JP 2012526149 A5 JP2012526149 A5 JP 2012526149A5 JP 2012510041 A JP2012510041 A JP 2012510041A JP 2012510041 A JP2012510041 A JP 2012510041A JP 2012526149 A5 JP2012526149 A5 JP 2012526149A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- kit
- agent
- thymosin peptide
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960005486 vaccine Drugs 0.000 claims description 36
- 108010046075 Thymosin Proteins 0.000 claims description 31
- 238000002255 vaccination Methods 0.000 claims description 16
- 102000007501 Thymosin Human genes 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 241000700605 Viruses Species 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 206010022000 influenza Diseases 0.000 claims 5
- 229960003971 influenza vaccine Drugs 0.000 claims 5
- 201000008827 tuberculosis Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 241000606161 Chlamydia Species 0.000 claims 2
- 206010008631 Cholera Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 241000709721 Hepatovirus A Species 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 201000005702 Pertussis Diseases 0.000 claims 2
- 206010035148 Plague Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000000474 Poliomyelitis Diseases 0.000 claims 2
- 206010037742 Rabies Diseases 0.000 claims 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 2
- 206010043376 Tetanus Diseases 0.000 claims 2
- 208000037386 Typhoid Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000003152 Yellow Fever Diseases 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010013023 diphtheria Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- 229960002520 hepatitis vaccine Drugs 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940124551 recombinant vaccine Drugs 0.000 claims 2
- 229940031626 subunit vaccine Drugs 0.000 claims 2
- 229940031572 toxoid vaccine Drugs 0.000 claims 2
- 201000008297 typhoid fever Diseases 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027249 Meningitis meningococcal Diseases 0.000 claims 1
- 201000010924 Meningococcal meningitis Diseases 0.000 claims 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 claims 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000009395 genetic defect Effects 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 208000022218 streptococcal pneumonia Diseases 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical group CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 1
- 229960004231 thymalfasin Drugs 0.000 claims 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17662509P | 2009-05-08 | 2009-05-08 | |
| US61/176,625 | 2009-05-08 | ||
| US23793209P | 2009-08-28 | 2009-08-28 | |
| US61/237,932 | 2009-08-28 | ||
| US32315510P | 2010-04-12 | 2010-04-12 | |
| US61/323,155 | 2010-04-12 | ||
| PCT/US2010/034221 WO2010129947A2 (en) | 2009-05-08 | 2010-05-10 | Alpha thymosin peptides as vaccine enhancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057490A Division JP5766894B2 (ja) | 2009-05-08 | 2015-03-20 | ワクチン増強剤としてのαチモシンペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526149A JP2012526149A (ja) | 2012-10-25 |
| JP2012526149A5 true JP2012526149A5 (enExample) | 2015-05-14 |
Family
ID=43050921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510041A Withdrawn JP2012526149A (ja) | 2009-05-08 | 2010-05-10 | ワクチン増強剤としてのαチモシンペプチド |
| JP2015057490A Active JP5766894B2 (ja) | 2009-05-08 | 2015-03-20 | ワクチン増強剤としてのαチモシンペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057490A Active JP5766894B2 (ja) | 2009-05-08 | 2015-03-20 | ワクチン増強剤としてのαチモシンペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8716012B2 (enExample) |
| EP (1) | EP2427213B1 (enExample) |
| JP (2) | JP2012526149A (enExample) |
| CN (1) | CN102458470B (enExample) |
| ES (1) | ES2537785T3 (enExample) |
| WO (1) | WO2010129947A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0518571A2 (pt) * | 2004-12-06 | 2008-11-25 | Sciclone Pharmaceuticals Inc | peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer |
| WO2012109106A1 (en) * | 2011-02-09 | 2012-08-16 | Sciclone Pharmaceuticals, Inc. | Thymosin alpha peptide for preventing, reducing the severity of, and treating infection |
| EP2768528A1 (en) * | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
| US20130296223A1 (en) * | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| CN103145853B (zh) * | 2013-03-05 | 2014-06-11 | 河南科技大学 | 重组Tα1-BP5融合肽、基因、工程菌及应用 |
| CN109793891A (zh) * | 2017-11-17 | 2019-05-24 | 韩震 | 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法 |
| CN112239784A (zh) * | 2019-07-19 | 2021-01-19 | 首都医科大学附属北京佑安医院 | Ifitm3多态性在制备检测老年肾透析患者分泌h3n2抗体水平产品中的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8018A (en) * | 1851-04-01 | Improvement in seed-planters | ||
| US4077949A (en) | 1973-12-28 | 1978-03-07 | Sloan-Kettering Institute For Cancer Research | Polypeptide hormones of the thymus |
| DE2604845A1 (de) | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| US4079127A (en) | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
| DE3100974A1 (de) | 1980-01-18 | 1982-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente |
| US4612365A (en) | 1980-03-25 | 1986-09-16 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften | Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments |
| US4560676A (en) | 1980-04-07 | 1985-12-24 | The Rockefeller University | N.sup.α -desacetylthymosinα1 and process |
| US4293455A (en) | 1980-04-07 | 1981-10-06 | Rockefeller University | N.sup.α -Desacetylthymosinα1 and process |
| US4361673A (en) | 1980-09-19 | 1982-11-30 | American Home Products Corporation | Polypeptide compositions |
| US4444757A (en) | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| US6106868A (en) | 1990-08-24 | 2000-08-22 | The Board Of Governors Of Wayne State University | Method for the treatment of hepatitis |
| TW224053B (enExample) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| US5308833A (en) | 1992-02-06 | 1994-05-03 | Sciclone Pharmaceuticals | Method for treating hepatitis B carriers with minimal disease |
| US5620896A (en) | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| US5432165A (en) | 1992-04-06 | 1995-07-11 | Oclassen Pharmaceuticals, Inc. | Methods for the treatment of infection caused by Hepatitis B virus (HBV) |
| AU4671193A (en) | 1992-07-13 | 1994-01-31 | Kenneth E. Sherman | Composition and method of treating hepatitis b |
| CN1094310A (zh) | 1992-12-15 | 1994-11-02 | 托马斯·C·梅里根 | 人体免疫缺陷性病毒感染用组合式化学疗法 |
| CN1072961C (zh) | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
| US6200952B1 (en) | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| TW249754B (enExample) | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
| US5750501A (en) | 1993-11-05 | 1998-05-12 | Alpha 1 Biomedicals, Inc. | Method and composition for treatment of patients having decompensated liver disease |
| WO1995012405A1 (en) | 1993-11-05 | 1995-05-11 | Alpha 1 Biomedicals, Inc. | Method and composition for treatment of patients having decompensated liver disease |
| US5888980A (en) | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5880980A (en) * | 1996-09-30 | 1999-03-09 | Rockwell International Corporation | Distributed decimation sample rate conversion |
| US5939423A (en) | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| EP1317929A3 (en) | 1997-09-21 | 2003-07-02 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection |
| EP1213029A1 (en) | 1998-05-15 | 2002-06-12 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| DK1087778T3 (da) | 1998-06-08 | 2005-12-19 | Hoffmann La Roche | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C |
| US20050037018A1 (en) * | 2003-06-20 | 2005-02-17 | Innogentics N.V. | HCV combination therapy |
| US6288033B1 (en) | 1998-09-25 | 2001-09-11 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir |
| CA2418085A1 (en) | 2000-08-07 | 2002-02-14 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| US20050020495A1 (en) | 2001-10-24 | 2005-01-27 | Martins Eduardo Bruno Guimaraes | Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| BR0213554A (pt) | 2001-10-26 | 2004-10-26 | Rhode Island Hospital | Timosina para aumento da imunização genética |
| AU2002342151B2 (en) | 2001-10-26 | 2007-07-19 | Immuno-Rx, Inc. | Immunotherapy for reversing immune suppression |
| UA80957C2 (en) | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| US20070036744A1 (en) | 2003-04-23 | 2007-02-15 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| US20100311656A1 (en) | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| BRPI0518571A2 (pt) * | 2004-12-06 | 2008-11-25 | Sciclone Pharmaceuticals Inc | peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer |
| CN100341571C (zh) * | 2005-09-16 | 2007-10-10 | 孙介光 | 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用 |
| PT2012816E (pt) | 2006-05-02 | 2012-08-17 | Sigma Tau Ind Farmaceuti | Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus |
| WO2007134908A2 (en) | 2006-05-19 | 2007-11-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of thymosin alpha 1 for the treatment of immunological diseases |
| AU2008338594A1 (en) | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA) |
-
2010
- 2010-05-10 CN CN201080030714.7A patent/CN102458470B/zh active Active
- 2010-05-10 EP EP10772928.7A patent/EP2427213B1/en active Active
- 2010-05-10 JP JP2012510041A patent/JP2012526149A/ja not_active Withdrawn
- 2010-05-10 WO PCT/US2010/034221 patent/WO2010129947A2/en not_active Ceased
- 2010-05-10 US US12/776,976 patent/US8716012B2/en active Active
- 2010-05-10 ES ES10772928.7T patent/ES2537785T3/es active Active
-
2015
- 2015-03-20 JP JP2015057490A patent/JP5766894B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sulczewski et al. | Nanoparticle vaccines against viral infections | |
| JP2012526149A5 (enExample) | ||
| Jabbal-Gill | Nasal vaccine innovation | |
| Raghuwanshi et al. | Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein | |
| CN104027324B (zh) | 一种可溶性微针疫苗贴片及其制备方法 | |
| EP2647387B1 (en) | Vaccine Composition | |
| EP2117590B1 (en) | Non-specific immunostimulating agents | |
| JP5190628B2 (ja) | 混合免疫賦活剤を含む新規ワクチン | |
| Dong et al. | Polycationic HA/CpG nanoparticles induce cross-protective influenza immunity in mice | |
| JP2011522874A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP5766894B2 (ja) | ワクチン増強剤としてのαチモシンペプチド | |
| Cossette et al. | Intranasal subunit vaccination strategies employing nanomaterials and biomaterials | |
| US20200054571A1 (en) | Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles | |
| JP2010506926A5 (enExample) | ||
| Wei et al. | Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms | |
| Kiyono et al. | Nasal vaccines for respiratory infections | |
| Pan et al. | A surfactin lipopeptide adjuvanted hepatitis B vaccines elicit enhanced humoral and cellular immune responses in mice | |
| Taghizadeh et al. | Nasal administration of M2e/CpG-ODN encapsulated in n-trimethyl chitosan (TMC) significantly increases specific immune responses in a mouse model | |
| Zhang et al. | Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases | |
| Dong et al. | Engineered nanoparticulate vaccines to combat recurring and pandemic influenza threats | |
| Hendy et al. | Preclinical developments in the delivery of protein antigens for vaccination | |
| Zhu et al. | Promising adjuvants and platforms for influenza vaccine development. Pharmaceutics. 2021; 13 (1): 68 | |
| US20130122045A1 (en) | Cross-Protective Influenza Vaccine | |
| CN103517713A (zh) | 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽 |